Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.

Hdl Handle:
http://hdl.handle.net/10147/126114
Title:
Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.
Authors:
Caiazza, F; McCarthy, N S; Young, L; Hill, A D K; Harvey, B J; Thomas, W
Affiliation:
Department of Molecular Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Citation:
Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. 2011, 104 (2):338-44 Br. J. Cancer
Journal:
British journal of cancer
Issue Date:
18-Jan-2011
URI:
http://hdl.handle.net/10147/126114
DOI:
10.1038/sj.bjc.6606025
PubMed ID:
21119660
Additional Links:
http://www.nature.com/bjc/journal/v104/n2/pdf/6606025a.pdf
Abstract:
The eicosanoid signalling pathway promotes the progression of malignancies through the production of proliferative prostaglandins (PGs). Cytosolic phospholipase A(2)α (cPLA(2)α) activity provides the substrate for cyclooxygenase-dependent PG release, and we have previously found that cPLA(2)α expression correlated with EGFR/HER2 over-expression in a small number of breast cancer cell lines.; The importance of differential cPLA(2)α activity in clinical breast cancer was established by relating the expression of cPLA(2)α in tissue samples from breast cancer patients, and two microarray-based gene expression datasets to different clinicopathological and therapeutic parameters.; High cPLA(2)α mRNA expression correlated with clinical parameters of poor prognosis, which are characteristic of highly invasive tumours of the HER2-positive and basal-like subtype, including low oestrogen receptor expression and high EGFR expression. High cPLA(2)α expression decreased overall survival in patients with luminal cancers, and correlated with a reduced effect of tamoxifen treatment. The cPLA(2)α expression was an independent predictive parameter of poor response to endocrine therapy in the first 5 years of follow-up.; This study shows a role of cPLA(2)α in luminal breast cancer progression, in which the enzyme could represent a novel therapeutic target and a predictive marker.
Item Type:
Article
Language:
en
MeSH:
Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Cytosol; Female; Humans; Oligonucleotide Array Sequence Analysis; Phospholipases A2; Prognosis; RNA, Messenger; Receptor, Epidermal Growth Factor; Reverse Transcriptase Polymerase Chain Reaction
ISSN:
1532-1827

Full metadata record

DC FieldValue Language
dc.contributor.authorCaiazza, Fen
dc.contributor.authorMcCarthy, N Sen
dc.contributor.authorYoung, Len
dc.contributor.authorHill, A D Ken
dc.contributor.authorHarvey, B Jen
dc.contributor.authorThomas, Wen
dc.date.accessioned2011-03-29T14:33:48Z-
dc.date.available2011-03-29T14:33:48Z-
dc.date.issued2011-01-18-
dc.identifier.citationCytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. 2011, 104 (2):338-44 Br. J. Canceren
dc.identifier.issn1532-1827-
dc.identifier.pmid21119660-
dc.identifier.doi10.1038/sj.bjc.6606025-
dc.identifier.urihttp://hdl.handle.net/10147/126114-
dc.description.abstractThe eicosanoid signalling pathway promotes the progression of malignancies through the production of proliferative prostaglandins (PGs). Cytosolic phospholipase A(2)α (cPLA(2)α) activity provides the substrate for cyclooxygenase-dependent PG release, and we have previously found that cPLA(2)α expression correlated with EGFR/HER2 over-expression in a small number of breast cancer cell lines.-
dc.description.abstractThe importance of differential cPLA(2)α activity in clinical breast cancer was established by relating the expression of cPLA(2)α in tissue samples from breast cancer patients, and two microarray-based gene expression datasets to different clinicopathological and therapeutic parameters.-
dc.description.abstractHigh cPLA(2)α mRNA expression correlated with clinical parameters of poor prognosis, which are characteristic of highly invasive tumours of the HER2-positive and basal-like subtype, including low oestrogen receptor expression and high EGFR expression. High cPLA(2)α expression decreased overall survival in patients with luminal cancers, and correlated with a reduced effect of tamoxifen treatment. The cPLA(2)α expression was an independent predictive parameter of poor response to endocrine therapy in the first 5 years of follow-up.-
dc.description.abstractThis study shows a role of cPLA(2)α in luminal breast cancer progression, in which the enzyme could represent a novel therapeutic target and a predictive marker.-
dc.language.isoenen
dc.relation.urlhttp://www.nature.com/bjc/journal/v104/n2/pdf/6606025a.pdfen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCohort Studies-
dc.subject.meshCytosol-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshOligonucleotide Array Sequence Analysis-
dc.subject.meshPhospholipases A2-
dc.subject.meshPrognosis-
dc.subject.meshRNA, Messenger-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction-
dc.titleCytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.en
dc.typeArticleen
dc.contributor.departmentDepartment of Molecular Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.en
dc.identifier.journalBritish journal of canceren
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.